Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Hobday

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Cancer|May 12, 2017
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinomaRobert R McWilliams, Nathan R Foster, Michelle R Mahoney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2018
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer PatientsKimberly R Kalli, Matthew S Block, Pashtoon M Kasi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437Monica M Reinholz, Kathleen A Kitzmann, Kathleen Tenner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinomaTimothy J Hobday, John W Kugler, Michelle R Mahoney, et al.
Breast Cancer Research and Treatment|October 27, 2010
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agentsPamela J Goodwin, Vuk Stambolic, Julie Lemieux, et al.
Endocrine-Related Cancer|September 13, 2023
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumorsSonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2019
Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope VaccineKeith L Knutson, Matthew S Block, Nadine Norton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2018
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)Kathy D Miller, Anne O'Neill, William Gradishar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2011
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meetingMatthew H Kulke, Lillian L Siu, Joel E Tepper, et al.
The New England Journal of Medicine|February 11, 2011
Everolimus for advanced pancreatic neuroendocrine tumorsJames C Yao, Manisha H Shah, Tetsuhide Ito, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Cancer|May 12, 2017
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinomaRobert R McWilliams, Nathan R Foster, Michelle R Mahoney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2018
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer PatientsKimberly R Kalli, Matthew S Block, Pashtoon M Kasi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437Monica M Reinholz, Kathleen A Kitzmann, Kathleen Tenner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinomaTimothy J Hobday, John W Kugler, Michelle R Mahoney, et al.
Breast Cancer Research and Treatment|October 27, 2010
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agentsPamela J Goodwin, Vuk Stambolic, Julie Lemieux, et al.
Endocrine-Related Cancer|September 13, 2023
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumorsSonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2019
Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope VaccineKeith L Knutson, Matthew S Block, Nadine Norton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2018
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)Kathy D Miller, Anne O'Neill, William Gradishar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2011
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meetingMatthew H Kulke, Lillian L Siu, Joel E Tepper, et al.
The New England Journal of Medicine|February 11, 2011
Everolimus for advanced pancreatic neuroendocrine tumorsJames C Yao, Manisha H Shah, Tetsuhide Ito, et al.
Pageof 8